Next Article in Journal
Re-Examining Genetic Screening and Oral Contraceptives: A Patient-Centered Review
Previous Article in Journal
Association of TLR4 Polymorphisms, Expression, and Vitamin D with Helicobacter pylori Infection
Article Menu

Export Article

Open AccessReview
J. Pers. Med. 2019, 9(1), 3; https://doi.org/10.3390/jpm9010003

Colorectal Cancer Biomarkers in the Era of Personalized Medicine

1
Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
2
Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
3
Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USA
*
Author to whom correspondence should be addressed.
Received: 3 December 2018 / Revised: 10 January 2019 / Accepted: 10 January 2019 / Published: 14 January 2019
Full-Text   |   PDF [261 KB, uploaded 14 January 2019]

Abstract

The 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory setting, which appears to benefit a small proportion of patients. Until recently, rat sarcoma (RAS) mutations remained the only genomic biomarker to assist with therapy selection in metastatic colorectal cancer. Next generation sequencing has unveiled many more potentially powerful predictive genomic markers of therapy response. Importantly, there are also clinical and physiologic predictive or prognostic biomarkers, such as tumor sidedness. Variations in germline pharmacogenomic biomarkers have demonstrated usefulness in determining response or risk of toxicity, which can be critical in defining dose intensity. This review outlines such biomarkers and summarizes their clinical implications on the treatment of colorectal cancer. It is critical that clinicians understand which biomarkers are clinically validated for use in practice and how to act on such test results. View Full-Text
Keywords: biomarker; prognostic; predictive; somatic; germline; pharmacogenomics; personalized medicine biomarker; prognostic; predictive; somatic; germline; pharmacogenomics; personalized medicine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Patel, J.N.; Fong, M.K.; Jagosky, M. Colorectal Cancer Biomarkers in the Era of Personalized Medicine. J. Pers. Med. 2019, 9, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top